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2. Abbreviations 
x ȕ –TG ȕ-thromboglobulin
x ACS                   Acute coronary syndromes 
x AP1                    Activator protein 1
x APC                   Antigen presenting cell 
x ATII                   Angiotensin II 
x BMP                   Bone morphological protein
x CAD                   Coronary Artery Disease 
x CD40L               CD40 ligand=CD154 
x CTAPIII             Connective tissue-activating peptide III  
x DARC                Duffy antigen receptor for chemokines 
x DC                     Dendritic cell
x FSH                    Follicle-stimulating hormone 
x GRO                  Growth Related Oncogene 
x HVEM               Herpes virus entry mediator  
x ICAM-1             Intercellular adhesion molecule-1  
x LDL                   Low Density Lipoprotein 
x IFN-Ȗ                 Interferon-gamma 
x LIGHT    Homologous to Lymphotoxins, exhibits Inducible expression,
                                 and  competes with herpes simplex virus (HSV) Glycoprotein
                                 for Herpes virus entry mediator (HVEM/TR2), a receptor 
                                 expressed by T lymphytes, = TNFSF14                   
x IL                       Interleukin 
x LOX-1               Lecitin-like oxidized low-density lipoprotein receptor-1 
x LPS                    Lipopolysaccaride 
x LTE                    Lymphotoxin E
x MCP-1               Monocyte chemoattractant protein-1 
x MI                      Myocardial infarction 
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x MIP                    Macrophage inflammatory protein 
x MP                     Microparticles 
x MMP                  Metalloproteinase 
x NAP-2               Neutrophil-activating peptide-2 
x (NF)țB              Nuclear factor- țB
x NO                     Nitric-oxide
x NSTEMI            Non-ST-elevation MI 
x oxLDL               Oxidized low-density protein 
x PBMC                Peripheral blood mononuclear cells        
x PF-4                   Platelet factor-4 
x R                        Receptor 
x RANTES Regulated upon Activation Normal T cell Expressed and
Secreted
x RNA                  Ribonucleic acid 
x ROS                   Reactive oxygen species 
x SMC                  Smooth muscle cells 
x SRA                   Scavenger receptor A 
x SR-PSOX          Scavenger receptor that binds phosphatidylserine and oxidized
                                 lipoprotein 
x STEMI               ST-elevation M 
x TF                      Tissue factor
x TGF- ȕ               Transforming growth factor-beta                 
x TNF- Į               Tumor necrosis factor-alpha 
x VCAM-1           Vascular cell-adhesion molecule 1 
x VLA-4               Very late antigen 4
x vWF                   von Willebrand factor 
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4. Introduction 
4.1 Coronary artery disease – general aspects 
Cardiovascular disease is the most common cause of death in western countries despite changes in 
lifestyle and the use of new therapeutic modalities to lower systemic cholesterol levels. 
Atherosclerotic disorders are also recognized as an increasing cause of significant mortality and 
morbidity in the developing world. A better understanding of the pathogenic mechanisms of this 
disorder, potentially leading to new treatment modalities, could therefore be of major importance 
to society.
Atherosclerosis is a progressive disease in large- and medium-sized arteries in which lipids, 
extracellular matrix and activated smooth muscle cells (SMC) accumulate in the arterial wall 
resulting in growth of an atherosclerotic plaque.1, 2 With the formation of fatty streaks, we are 
already early in life predisposed to this disorder. Fatty streaks, containing mostly lipid-laden 
macrophages and T-cells, present as asymmetrical focal thickening of the intima. These early 
plaques though not clinically significant, can later disappear or evolve into more fibrotic and 
complex lesions characterized by a necrotic core with lipid rich debris surrounded by a cap of 
SMC and collagen rich matrix, eventually leading to clinical manifestations of coronary heart 
disease and other forms of atherosclerotic disorders such as cerebrovascular and peripheral artery 
disease.1, 2
With progression of coronary atherosclerosis, the plaque extends eccentrically without 
compromising the lumen. As the atherosclerotic disease worsens, a luminal encroachment of the 
plaque can result in hemodynamic obstruction and subsequently symptoms of stable angina 
pectoris.1, 2 In contrast to progressive stenosis, acute coronary syndromes (ACS), i.e., unstable 
angina and acute myocardial infarction (MI), including both ST-elevation MI (STEMI and non-
ST-elevation MI (NSTEMI), seem to be caused by a sudden physical disruption of atherosclerotic 
plaques triggering thrombus formation and vascular obstruction.3 Two major types of physical 
disruption of atherosclerotic plaques may occur.4 Firstly, superficial erosion of the endothelial 
monolayer uncover subendothelial collagen and von Willebrand factor (vWF) promoting platelet 
adhesion and activation with subsequent thrombus formation. The second and most common 
mechanism of plaque disruption involves rupture of the fibrous cap.4, 5 This cap normally serves to 
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sequester the thrombogenic lipid-rich core in the atheroma. However, during fissure formation, 
often occurring in the plaque shoulder, there is a marked activation of the coagulation cascade and 
platelets, and such mechanisms may account for approximately three-quarter of ACS. However, 
although some general aspects have been established, the pathogenic mechanisms that lead to 
plaque destabilization are still incompletely understood.
4.2 Atherogenesis – general aspects 
The earliest changes that precede the atherosclerotic lesions take place in the intima which is the 
innermost layer of an artery, consisting of loose connective tissue and covered by a monolayer of 
endothelium. The endothelium is a selectively permeable barrier, and at typical predilection sites 
with decreased shear stress and increased turbulence, alterations in endothelial morphology, 
permeability as well as surface molecules are seen. At these sites, low-density lipoprotein (LDL) 
diffuses from the blood into the subendothelial matrix where it can be modified by oxidation, 
glycosylation, aggregation or associated with proteoglycans and thus trapped in the subendothelial 
space. The infiltration and retention of LDL in the arterial intima initiate an inflammatory response 
in the artery wall. Modification of LDL, through oxidation or enzymatic attack in the intima, leads 
to the release of phospholipids that can activate endothelial cells, preferentially at sites of
hemodynamic strain. Patterns of hemodynamic flow typical for atherosclerosis-prone segments 
(low average shear but high oscillatory shear stress) cause increased expression of adhesion
molecules and inflammatory genes by endothelial cells. Therefore, hemodynamic strain and the 
accumulation of lipids may initiate an inflammatory process in the artery. Thus, although several 
factors may be involved, the interaction between modified LDL and endothelial cells seem to be 
the initial event in atherogenesis contributing to several co-existing processes (e.g., inflammation 
and pro-coagulation) eventually leading to a manifest atherosclerotic plaque.  
The degree in witch LDL is modified varies greatly. Through progressive modification by 
reactive oxygen species (ROS) from macrophages and endothelial cells as well as 
myeloperoxidases and lipases from neutrophils, it can, as highly oxidized LDL (oxLDL), be 
internalized in macrophages. This interaction between oxidized modified LDL and macrophages 
within the atherosclerotic lesion, mediated through various scavenger receptors like CD36, 
scavenger receptor A (SRA), and Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), 
is a major event in atherogenesis turning macrophages into lipid-laden foam cells. These foam cell 
11
macrophages are important actors in atherogensis within the atherosclerotic lesion, contributing to 
lipid accumulation, inflammation, matrix degrading and thrombus formation.2, 6-8
The formation of a fibrous cap is an important step in atherogenesis. This formation 
develops as a result of a multi-etiological process. Firstly, death of foam cells through apoptosis or 
necrosis results in accumulation of extracellular lipids and cell debris. Second, the mutual 
activation of T cells and macrophages results in production of various cytokines and growth 
factors witch stimulate SMC proliferation, migration as well as their production of extracellular 
matrix. Third, a similar influence is seen as a result of elevated homocysteine and blood pressure, 
clinical findings commonly seen patients with CAD. Increased homocysteine levels may injure the 
endothelium, at least partly involving ROS-related mechanisms, resulting in stimulation of SMC. 
As for hypertension, elevated Angiotensin II (ATII) levels may play a pathogenic role. Not only 
does ATII affect proliferation and hypertrophy of SMC by augmenting intracellular calcium 
through binding to SMC receptors, it also acts as a potent vasoconstrictor by itself or by decreasing 
nitric oxide (NO) levels, thus impairing the arterial flow. Hence, with the influx and proliferation 
of SMC, an elastic fibrous cap is formed, preventing the contact between the blood and the pro-
thrombotic material in the lesions. Although this process may lead to narrowing of the arterial 
lumen, it will also promote plaque stability preventing plaque rupture and development of ACS.2, 7, 
9-15
4.3 Acute coronary syndromes – shifting focus from stenotic vessels to plaque 
disruption
Our classical view held that acute MI usually occurred due to a critically narrowed coronary 
arterial lumen, detectable by angiography. However, careful pathologic and angiographic studies 
in the 1980s determined that fissuring or rupture of the thin fibrous cap of a coronary atheroma 
with preserved lumen often triggers acute fatal thrombosis. Thus, angiographic studies have shown 
that the culprit lesion in acute MI may not necessarily cause hemodynamically relevant (flow-
limiting) stenosis of the coronary arteries.16 Moreover, several large clinical studies have shown 
that while cholesterol lowering with statins substantially reduces the occurrence of acute adverse 
coronary events, such therapy surprisingly produces only slight reduction in arterial obstruction 
estimated by angiography.17, 18 A striking difference between patients with unstable and stable 
angina is the higher incidents of new coronary events in the unstable group.19 Surprisingly, in 
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almost half of the cases such recurrent events are unrelated to the initial culprit lesion but arise 
from complications in other segments of the coronary vasculature. In support of this notion, 
several angiographic and angioscopic studies have revealed that all major coronary arteries are 
widely diseased displaying multiple vulnerable plaques in unstable patients.20, 21 These new 
findings have shifted the goal of therapy towards plaque stabilization rather than enlargement of 
the lumen. In order to achieve such a goal, a better understanding of the biology of the 
atherosclerotic plaques and the processes leading to plaque destabilization is needed.  
4.4 The role of inflammation in atherogenesis 
Atherosclerosis is a progressive multifactor disease in which lipids, extracellular matrix, and 
activated vascular SMC accumulate in the arterial wall resulting in growth of an atherosclerotic 
plaque. Recent research has shown that inflammation plays a key role in this process. Hence, 
immune cells dominate early atherosclerotic lesions, their effectors molecules accelerate 
progression of the lesions, and activation of inflammation can elicit ACS.7, 14, 22
In this inflammatory disorder, leukocyte recruitment and transmigration to the vascular lesions, 
which is regulated through a multistep process where functions mutually overlap, is a major 
pathogenic event. The initial adhesion or rolling of leucocytes to the endothelium is mediated by 
selectins such as intercellular adhesion molecule-1 (ICAM-1), platelet selectin (P-selectin) and 
endothelial selectin (E-selectin), and their binding to carbohydrate ligands on the leucocytes. 
Further, through an integrin-mediated arrest on the activated endothelium, a firm adhesion is made 
when monocytes and T cells bind to vascular cell-adhesion molecule-1 (VCAM-1) expressing 
endothelial cells through their intergrin very late antigen-4 (VLA-4). A subsequent transmigration 
or transendothelial diapedesis of leukocytes to subendothelial tissue is induced by and towards a 
locally produced chemokine gradient generated of, among others, monocyte chemoattractant 
protein-1 (MCP-1), interleukin (IL)-8 and Regulated upon Activation Normal T cell Expressed and 
Secreted (RANTES). Cytokines such as chemokines, tumor necrosis factor-alpha (TNF-D, IL-1 
and interferon-gamma (IFN-J play a major role in this process leading to endothelial cell 
activation and recruitment and activation of leukocytes into the atherosclerotic lesion. Leukocyte 
infiltration and activation within the atherosclerotic plaque will further lead to increased 
production of inflammatory cytokines which again will further enhance leukocyte infiltration, as 
part of a pathogenic loop in atherogenesis. This persistent inflammation will also alter the 
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phenotype of macrophages and SMC within the atherosclerotic lesion. Thus, monocytes 
differentiate into macrophages in response to, among others, local production of macrophage 
colony stimulating factor (M-CSF). A further development to foam cells through uptake of 
modified lipoproteins by scavenger receptors is vastly regulated by cytokines such as TNF-Į, IL-6 
and IFN-Ȗ, turning macrophages into lipid-laden foam cells with an enhanced inflammatory, pro-
coagulant and matrix degrading potential. Moreover, inflammatory cytokines may also transform 
SMC from a contractile to a proliferative/secretory phenotype which is a hallmark of the vascular 
remodeling characterizing atherogenesis. 2, 7, 8, 12, 23
The presence of activated T cells in all stages of atherogenesis implies that also these cells 
are involved in aggravation of disease. Indeed, T cell deficient severe combined immunodeficiency 
mice on an apoE-knockout background develop less atherosclerotic disease than do 
immunocompetent apoE-knockout mice.24 On the other hand, transfer of CD4+ T cells into these 
immunodeficient atherosclerotic miceaccelerates the disease.24 However, while the pathogenic role 
of T cells in atherogenesis is well established, the complex function of the various T cell subsets in 
this disorder is far from clear. This, while activation of the so-called regulatory T cells, producing 
IL-10 and transforming growth factor-beta (TGF-E may be an interesting antiatherogenic target, 
activation of the inflammatory T helper type 1 (Th1) subset, leading to increased production of 
IFN-J, IL-2 and TNF-D, seems to be major atherogenic event promoting activation of macrophages 
and vascular SMC within the lesion.25 However, although the participation of inflammation in 
atherogensis is well established, the characterization of the various actors as well as their 
regulation and relative importance is far from clear. 
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Figure 1. Cytokines and chemokines in mononuclear cell recruitement and development of atherosclerotic 
lesions. A triggering event for leucocyte transmigration  to the vessel wall is the accumulation of intimal modified 
lipoprotein particles with a subsequent stimulation of the overlying endothelial cells to produce adhesions molecules 
such as selectins and integrins, as well as chemotactic proteins such as MCP-1. According to the multistep paradigm, 
leucocyte trafficking is initiated by selectin-mediated rolling followed by an integrin-dependent arrest on cytokine 
activated endothelium and transmigration induced by chemokines. Chemokine (i.e., RANTES and PF4) deposition on 
endothelial cells from activated platelets also contribute to the arrest of leucocytes. Extravasated macrophages (M) 
recognize LDL by scavenger receptors (i.e., SR-A and CD36) whose expression is mediated by cytokines such as 
TNF-D and INF-J. Through accumulation of modified LDL they transform into foam cells (FC). The death of foam 
cells results in a growing mass of extracellular lipids and debris, a necrotic core. The interaction of CD40 and CD40L 
stimulates T-cells and macrophages to express cytokines that can influence inflammation, SMC proliferation and 
migration with subsequent SMC derived extracellular matrix giving rise to a fibrous cap. 
4.5 Inflammation – potential mediator of plaque destabilization 
Several lines of evidence suggest that inflammation is an integral part not only of the chronic 
atherosclerotic process, but also of plaque destabilization leading to the development of ACS.
Thus, elevated circulating levels of inflammatory mediators such as inflammatory cytokines are 
found in patients with angina, particularly in those with unstable disease.26 Also, activated 
monocytes, T-cells and granulocytes have been demonstrated in patients with unstable angina with 
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particularly enhanced activation in cells isolated from coronary sinus.27 Moreover, accumulation of 
inflammatory cells such as macrophages and T-cells seems to be an important feature of the active 
stages of atherosclerosis.14 Hence, in atherectomy specimens and necropsy studies, disrupted 
plaques typically display a large lipid core, thin fibrous cap, reduced number of smooth muscle 
cells accompanied by a large numbers of monocyte-derived macrophages and activated T-cells.28-
30 Furthermore, it seems that the pan-coronary vulnerability during ACS may result from a 
widespread coronary inflammation. Hence, Buffon et al have recently reported a transcoronary 
neutrophil activation in patients with unstable angina, occurring to a similar degree in the presence 
or absence of the culprit lesion.31 Moreover, inflammatory cytokines could promote tissue factor 
(TF) expression in macrophages, change endothelial cells into to a pro-coagulant phenotype by up-
regulate plasminogen activator inhibitor-1 (PAI-1) and down-regulate thrombomodulin expression 
as well as induce matrix metalloproteinase (MMP) activity in SMC and macrophages, promoting 
thrombus formation and matrix degrading within the atherosclerotic lesion.32 Finally, multiple 
studies have established inflammatory markers and in particular C-reactive protein (CRP) as 
markers of risk of future cardiovascular events.33, 34 Thus, CRP has proven remarkably robust as a 
marker of cardiovascular risk and has been found to give predictive value beyond that of 
traditional risk factors in CAD patients.  
Thus, it seems that complex and not yet clarified immunological mechanisms regulate not 
only the initiation but also the outcome of the atherosclerotic process, emphasizing the importance 
of further studies of these inflammatory mechanisms, trying to identify new targets for therapy in 
this disorder. 
4.6 Chemokines - important players in inflammation 
Chemokines, chemotactic cytokines, belong to a superfamily of chemoattractant cytokines 
involved in leukocyte recruitment and activation. These small polypeptide molecules of 8-10 kDa 
can be induced by cytokines, growth factors and some pathogenic stimuli such as oxidative stress 
and various microbes. The approximately 50 known chemokines can be segregated into four 
families on the basis of the number and spacing of the conserved cysteine residues in their 
sequences; — C–C, C–X–C, C–X3–C and C —  (Table1). The families of CXC, having a single 
amino acid interposed (e.g., IL-8 and growth related oncogene [GRO]-Į), and CC (e.g., MCP-1 
and RANTES) constitute the two major families. The third family, CX3C, contains fractalkine 
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(CX3CL1) as the only member, and the fourth C family comprises lyphotacins.35, 36 The CXC 
family can be further subdivided into two categories depending on the presence or absence of a 
three amino acid sequence, a glutamate-leucine-arginine (ELR) motif. In general the ELR+
chemokines are involved in the early inflammatory phase through attracting neutrophils, while 
ELR- chemokines act on lymphocytes. Moreover, the two different ELR group also have different 
aniogenic properties. Thus, while ELR+ chemokines are potent angiogenic factors, the ELR-
chemokines are anti-angiogenic. CC chemokines act primarily on monocytes, eosinophils, 
basophils and lymphocytes, but in the general there are more overlapping functions between CXC 
and CC chemokines than previously recognized.37
Each family of chemokines has a reciprocal family of seven-transmembrane G-protein-
coupled receptors, whereas most receptors bind more than one chemokine. Receptor activation can 
result in an array of events. Changes in cell shape can occur within seconds, facilitating cell 
movement toward the chemokine gradient. Also intracellular events are affected through changes 
in gene expression. Further, receptor activation can promote the release of contents in 
cytoplasmatic granules such as proteases, and induce Ca2+ influx to the cell with a subsequent 
generation of oxygen radicals and lipid mediators. Interestingly, chemokine receptors are 
constitutively expressed on some cells whereas inducible in others. Also, some constitutive 
receptors can be down-regulated, while the expression of others is restricted to a cell state of 
activation and differentiation. The chemokine receptor phenotype of inflammatory cells fluctuates 
during their differentiation and exposure to external stimuli. Duffy antigen receptor for 
chemokines (DARC) interacts with non-signaling molecules and act as a sink for chemokines, 
clearing them from the circulation. It is also the only known chemokine receptor that can bind both 
CC and CXC chemokines. The rapid binding of IL-8 to DARC may at least partly explain the low 
levels of IL-8 and perhaps also some other chemokines in the circulation.38-41
4.6.1 Homeostatic and inflammatory chemokines 
Chemokines were originally discovered through their ability to recruit various cell types into sites 
of inflammation, but it is now clear that they posses a wider role in immune homeostasis driving 
maturation, homing and activation of leucocytes. In this aspect, one can make a division into two 
functional classes of chemokines; the inflammatory and the homeostatic chemokines. 
Homeostatic chemokines are involved in the regulation of physiological lymphocyte 
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trafficking, a sort of a housekeeping function, as well as a directional migration and positioning 
within secondary lymphoid organs and tissues. There is a restricted constitutive production of the 
homeostatic chemokines (e.g., CC ligand [CCL]19, CCL21 and CXCL13), and elevated levels are 
found in thymus, lymph nodes as well as other lymphoid tissue interacting with their 
corresponding chemokine receptors, CCR7 and CXCR5, respectively. However, while the role of 
these chemokines in the migration of lymphocytes home from their sites of lymphopoiesis to 
secondary lymphoid organs where they encounter antigen in specialized compartments, or they 
egress from lymph nodes and eventually recirculate, recent studies suggest that these homeostatic 
chemokines also may regulate the migration of T and B lymphocytes through non-lymphoid 
tissues.38, 42-44
In contrast to the homeostatic chemokines that are constitutively expressed within 
secondary lymphoid organs, inflammatory chemokines are up-regulated during various 
inflammatory events. Inflammatory chemokines promote leukocyte infiltration and activation at 
the site of inflammation and their expression is inducible, primarily by inflammatory cytokines 
such as IL-1, TNF-D and IL-12 as well as by enhanced oxidative stress and toll-like receptor 
(TLR) activation (e.g., TLR2 and TLR4), involving activation of transcriptional factors such as 
nuclear factor NB (NFNB) TNF-Į).  Importantly, also traditional cardiovascular risk factors such as 
high levels of oxLDL and smoking (through ROS generation) might through monocyte activation 
or direct effects on T cells, lead to increased production of inflammatory chemokines.2, 11, 32, 45, 46
The inflammatory CC chemokine MCP-1 is the most thoroughly characterized chemokine, 
and a key mediator in monocyte trafficking, recruiting them to sites of trauma, bacterial infection 
and ischemia. The CXC chemokine IL-8 is another prototypic inflammatory chemokine, and 
similar to MCP-1, IL-8 will not only induce chemotaxis through recruiting inflammatory cells (for 
IL-8, principally neutrophils, the signature cell of acute inflammatory response), but also stimulate 
them to a higher activation state. Being rapidly synthesized at local sites of inflammation, resistant 
to relatively harsh external conditions persisting for a prolonged time, IL-8 is an ideal molecule to 
live at site of inflammation. 23, 47
4.6.2 Membrane bound chemokines 
Within the chemokine family of small chemotactic polypeptides CX3CL1 and CXCL16 are 
exceptional in that they are synthesized as transmembrane molecules and can be cleaved from the 
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cell surface to produce a soluble chemoattractant. As transmembrane molecules on the surface of 
endothelial cells, CX3CL1 and CXCL16 can interact with their receptors CX3CR1 and CXCR6, 
respectively, which are expressed on leukocyte subtypes. This interaction leads to cell-cell 
adhesion that is resistant to shear forces. Functionally, both chemokines appear to exert 
homeostatic and inflammatory activities. Thus, while basal expression of CX3CL1 or CXCL16 
may be relevant for positioning and survival of tissue-homing leukocytes, increased expression 
have been found during various inflammatory condition potentially contributing to leukocyte 
recruitment into inflamed tissue. Interestingly, it seems that the membrane-bound and the soluble 
form of these chemokines may exert different properties, but it remains to be clarified if some of 
the forms have predominantly a homeostatic or inflammatory function. In fact, the exact role of 
these distinct chemokines is not fully understood, and it is a challenge for future research to dissect 
and clarify the role of both the transmembrane and soluble forms of these chemokines in the 
pathophysiology of various human diseases.48, 49
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Table 1. Chemokines and their receptors 
 Family    Functual classification    Systematic name    Human ligand    Chemokine receptors 
                   CC            Inflammatory                        CCL1                   I-309                    CCR8 
                                                                  CCL2                    MCP-1                CCR2 
                                                                  CCL3                    MIP-Į                 CCR1, CCR5 
                                                                  CCL4                    MIP-1                 CCR5 
                                                                  CCL5                    RANTES            CCR1, CCR3, CCR5 
                                                                  CCL6                    Unknown            Unknown 
                                                                  CCL7                    MCP-3                CCR1,CCR2,CCR3 
                                                                  CCL8                    MCP-2                CCR3,CCR5c 
                                                                  CCL9/10               Unknown            CCR1 
                                                                  CCL11                  Eotaxin               CCR3 
                                                                  CCL12                  MCP-5                CCR2 
                                                                  CCL13                  MCP-4                CCR2, CCR3 
                                                                  CCL14                  HCC-1                CCR1, CCR5 
                                                                  CCL16                  HCC-4                CCR1, CCR2 
                                                                  CCL23                  MPIF-1               CCR1                                                         
                    Inflammatory, angiogenic     CCL15                 HCC-2                 CCR1, CCR3 
                    Inflammatory and homeo-    CCL17                  TARC                 CCR4 
                    static 
                                                                  CCL22                  MDC                   CCR4 
                    Homeostatic                          CCL18                  PARC                 Unknown 
                                                                  CCL19                  ELC/MIP-3ȕ       CCR7 
                                                                  CCL20                  LARC/MIP-3Į    CCR6 
                                                                  CCL21                  SLC                     CCR7   
                                                                  CCL2                    Eotaxin-2            CCR3 
                                                                  CCL5                    TECK                  CCR9 
                                                                  CCL26                  Eotaxin-3            CCR-3 
                                                                  CCL27                  CTACK              CCR10 
                                                                  CCL28                  MEC                   CCR3, CCR10 
C               Inflammatory                       XCL1                    Lymfotacin         XCR1 
                                                                  XCL2                    SCM-1ȕ              XCR2 
CXC         Inflammatory, angiogenic    CXCL1                 GRO-Į                CXCR2, CXCR1 
                                                                  CXCL2                 GRO- ȕ               CXCR2 
                                                                  CXCL3                 GRO-Ȗ                CXCR2 
                                                                  CXCL5                 ENA-78              CXCR2 
                                                                  CXCL6                 GCP-2                 CXCR1, CXCR2 
                                                                  CXCL7                 NAP-2                 CXCR1, CXCR2 
                                                                  CXCL8                 IL-8                     CXCR1, CXCR2 
                     Inflammatory, angiostatic    CXCL9                 MIG                    CXCR3 
                                                                  CXCL10               IP-10                   CXCR3 
                                                                  CXCL4                 PF4                     Unknown 
                                                                  CXCL11               I-TAC                 CXCR3a 
                     Homeostatic, angiogenic     CXCL12               SDF-1                  CXCR4 
                     Homeostatic                         CXCL13               BCA-1                CXCR5 
                                                                  CXCL14               BRAK                 Unknown 
                     Inflammatory                       CXCL16                                           CXCR6 
CXXXC   Inflammatory                       CX3CL1               Fractalkine           CX3CR1 
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I-309, a nameless human chemokine; MCP-1, monocyte chemoattractant protein; MIP, macrophage inflammatory 
protein; RANTES, regulated upon activation normal T cell expressed and secreted; HCC, human CC chemokine; 
MPIF, myeloid progenitor inhibitory factor; TARC, thymus-and-activation-regulated chemokine; MDC, macrophage-
derived chemokine; PARC, pulmonary and activation-regulated chemokine; ELC, (Ebl-1), EBL-1-ligand chemokine, 
LARC, liver- and activation-regulated chemokine, SLC, secondary lymphoid tissue chemokine, TECK, thymus-
expressed chemokine; CTACK, cutaneous T-cell-activating chemokine; MEC, mucosae-associated epithelial 
chemokine; SCM, Single C motif; GRO, growth related oncogene; ENA, epithelial neutrophil activating; GCP, 
granulocyte chemotactic protein; NAP, neutrophil-activating peptide; MIG, monokine-induced by IFN-Ȗ; IP, IFN-Ȗ
inducible protein; PF, platelet factor; I-TAC, IFN-inducible T-cell a chemoattractant; SDF-1, stromal cell-derived 
factor 1; BCA, B-cell attracting chemokine; BRAK, breast and kidney-expressed chemokine.     
4.7 The role of chemokines in atherogenesis
Several lines of evidence support an important role for chemokines in atherogenesis. Thus, there 
are several reports of raised serum levels of chemokines in CAD.50 Moreover, these chemotactic 
cytokines seem to be raised not only in circulation, but also within the atherosclerotic lesions.15
Hence, there are several reports of enhanced expression of both CXC-chemokines (e.g IL-8 and 
interferon-J-inducible-10 [IP-10]), CC-chemokines (e.g., MCP-1, leukotactin-1 [Lkn-1], and 
RANTES) as well as some of their corresponding receptors within atherosclerotic lesions. In 
addition to being a potent chemoattractant, several other leukocyte responses such as cell 
proliferation, enzyme secretion and induction of ROS, have been observed in vitro after chemokine 
stimulation).15 Moreover, beyond their effects on leukocytes, chemokines may also interfere with 
SMC migration and growth, as well as platelet activation.51, 52 Some of these responses may clearly 
be relevant to atherogenesis, and indeed, the co-expression of chemokines and their receptor within 
atherosclerotic lesions, involving various cell types such as T cells, macrophages, and vascular 
SMC, suggests their involvement not only in the regulation of lymphocyte recruitment into 
atherosclerotic lesions, but also in other processes with relevance to atherogenesis such as 
regulation of SMC phenotype. Furthermore, recent in vivo studies have shown that targeted 
disruption of the genes for MCP-1, CCR2 (i.e., MCP-1 receptor), CXCR2 (i.e., IL-8 receptor) and 
CX3CR1 (i.e., fractalkine receptor) significantly decreases atherosclerotic lesion formation and 
lipid deposition in mice prone to develop atherosclerotic lesions.53-55 These and other studies in 
gene modified mice, strongly suggest an important pathogenic role of chemokines and 
atherogenesis.
Notably, infiltration and activation of circulating T cells and monocytes into the 
atherosclerotic plaque may also be involved in the triggering of ACS.3 Again, chemokines may 
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play an important role in this immune-mediated plaque destabilization, not only by recruiting 
activated leukocytes into the atherosclerotic vessel wall, but also by directly contributing to plaque 
rupture and thrombus formation by enhancing the matrix degrading potential in macrophages by 
inducing TF and matrix MMPs in vascular SMC, and by promoting neovascularization within the 
atherosclerotic lesion which in turn may act as a conduit for the entry of leukocytes into sites of 
chronic inflammation.56-61 Chemokines could also promote plaque rupture by enhancing oxidative 
stress and apoptosis within the atherosclerotic lesions. In fact, angina patients have been found to 
have raised levels of both CC and CXC chemokines with particularly high concentration of IL-8, 
MCP-1, and macrophage inflammatory protein (MIP)-1Į in unstable disease, significantly 
correlated with enhanced oxidative stress in these patients.62 Consequently, chemokine 
receptor/ligand could be identified as potential important pathogenic mediators not only in the 
chronic atherosclerotic process, but also in plaque destabilization with subsequent development of 
ACS. However, their exact role as well as their relative importance is still unclear and much 
remains to be done to further enlighten the complexity of chemokine responses. 
4.8 Platelets – important cellular actors in atherogenesis
Platelets are blood cell fragments originating from megacaryocytes. With a mean cell surface of 8 
μm these anuclear, discoid cells circulate in the blood in a resting state with a circulating life of 7-
10 days. They contain a contractile system consisting of actin and myosin forming a cytoplasmatic 
three dimensional network as well as a network of shorter actin fibres and bundles of microtubles 
serving as the membrane skeleton and maintaining the discoid shape of the resting platelet. 
Platelets contain remnants of magacaryocyte ribonucleic acid (RNA), mitochondria, and three 
distinct granules; the electron dense granules, Į-granules and lysosomes which contain highly 
potent substances essential for haemostatic and inflammatory processes. Receptors responsible for 
adhesion, aggregation and signal transduction are located in the plasma membrane.   
When platelets are activated, for example through injury to the vascular wall with a 
subsequent adherence to the subendothelium, a further initiating of a cascade of signals from the 
membrane to the cytoplasm is seen. Furthermore, platelets undergo morphological changes, a so 
called outside-in signaling. Platelets go from being discoid with homogenous distribution of 
granules to spherical with centralized granules and pseudopodia originating from the plasma 
membrane.63 This much more efficient platelet undergoes exocytosis of its centralized granules, 
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not only resulting in an extracellular milieu able to attract more platelets, but through internalizing 
new proteins like P-selectin and CD40ligand (CD40L) in the plasma membrane, mediate platelet 
binding to neutrophils, monocytes and endothelial cells.63-65 Activation of platelets is also 
associated with the binding of fibrinogen and/or vWF to their major receptor GPIIb-IIIa which is 
essential for platelet bridging and subsequent platelet aggregation.66
Later events in the platelet activation cascade include rearrangement of the platelet 
membrane converting it to a procoagulant surface.67 Microparticles (highly procoagulant small  
vesicles formed from the platelet surface), as well as adhesion molecules, such as soluble P-
selectin, are shed from the platelet surface into the circulation as stimuli for leukocytes and 
endothelial cells. Taken together, these events culminate in the assembly of the prothrombinase 
complex leading to formation of a fibrin containing platelet plug and subsequent clot retraction.67-
71
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Figure 2. Resting platelet illustrating the different cell compartments and organelles with contents. D, D-granule; 
ȕ-TG, ȕ-thromboglobulin; ADP, adenosine diphosphate; CD62P, P-selectin; D, dense granules; DTS, dense tubular 
system; FV, Factor V; GDP, guanosine diphosphate; GP, glycoprotein; L, lysosome; M, mitochondria, PAI-1, 
plasminogen activator inhibitor-1; PDGF, platelet-derived growth factor; PF4, platelet factor-4; R, receptor; RANTES 
Regulated upon Actication Normal T cell Expressed and Secreted; TFPI, tissue factor pathway inhibitor; TGF- ȕ,
transforming growth factor-ȕ; TSP, thrombospondin; VEGF, vascular endothelial growth factor; vWF, von Willebrand 
factor.
4.9 Platelet-mediated inflammation 
It is well established that platelets contribute to the pathogenesis of atherosclerosis and ACS by 
promoting thrombus formation. However, recent studies suggest that these cells also may trigger 
an acute coronary event through other mechanisms, i.e., stimulation of an inflammatory response 
within the atherosclerotic plaque. Thus, along with their traditional role in thrombosis and 
haemostasis, a growing body of evidence links platelets to an array of other processes including 
inflammatory responses. Firstly, a variety of growth factors and inflammatory mediators are stored 
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in Į-granules and released upon activation. These include platelet factor-4 (PF-4), ȕ-
thromboglobulin (ȕ-TG), RANTES, GRO-Į along with recent reported CD40L.64, 72-74 Second, 
platelets do not only contain and express inflammatory mediators, but may upon activation also 
induce the expression of such substances in monocytes/macrophages.75 Actually, upon activation 
platelets express P-selectin on their surface. Through ligation with its counterpart on 
monocytes/macrophages, P-selectin has the potential to enhance the activation of the
transcriptional factor NFNB76, a factor required for expression of chemokines, TNF-D and several 
other gene products playing a key role in inflammation. Notably, recent studies suggest that
platelets also may modulate the function of other leukocyte subsets (e.g., natural killer cells, 
neutrophils, and T cells) and they have been found to enhance chemotactic and adhesive properties 
of endothelial cells as well as IL-1 production in vascular SMC.77, 78 Finally, platelets may not only 
promote an inflammatory response in leucocytes and endothelial cells, but may also themselves 
respond to inflammatory mediators produced by these cells. In fact, platelets have recently been
found to express several chemokine receptors that upon stimulation endorse platelet activation.79
 Recently, much attention has been focused on the role of platelet-derived CD40L in this 
inflammatory loop between platelets and other cells. CD40L, a transmembrane protein belonging 
to the TNF superfamily, was originally identified on CD4+ T cells, but has recently also been 
found on mast cells, basophils, eosinophils as well as on activated platelets.80 Soluble CD40L 
(sCD40L) is found elevated in coronary disease in particular in patients with ACS81, and has been 
associated with increased cardiovascular risk in apparently healthy women.82 Several lines of 
evidence suggest that these findings not only represent epiphenomena, but also may reflect 
important pathogenic processes in these patients. Both membrane-bound and sCD40L may interact 
with CD40, which is constitutively expressed on a wide range of cells such as macrophages, 
endothelial cells, and vascular smooth muscle cells as well as on platelets, resulting in various 
inflammatory responses.80 Thus, in vitro stimulation of CD40 signaling in atheroma-derived cells 
results in the production of cytokines, TF, MMPs and adhesion molecules.83-85 In vivo, an 
important role for the CD40L-CD40 interaction in atherogenesis was demonstrated using mice 
deficient in CD40L and apoE showing a dramatic decrease in plaque area in these mice compared 
with normal apoE-deficient animals.86 The possible plaque stabilizing effect of CD40L 
neutralization was further demonstrated in another study where the administration of anti-CD40L 
antibody to apoE-deficient mice induced a stable plaque phenotype.87 However, and with 
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relevance to other cytokines, the relative importance of the soluble and membrane-form of CD40L 
in mediating its biological effects is still debated. Moreover, recent studies suggest that release 
mechanism of sCD40L from platelet are different from that of Dgranula release88, 89-91, further 
complicating the regulation and biological significance of this platelet-derived member of the TNF 
superfamily. Nevertheless, it is now well established that upon activation platelets may release and 
express inflammatory mediators, induce an inflammatory response within leucocytes, and respond 
with activation to several of the inflammatory mediators produced by these cells.92 This platelet-
leucocyte cross talk seems to involve a wide range of mediators such as chemokines, adhesions 
molecules, ROS, and cytokines.93-95 It is tempting to hypothesise that this inflammatory interaction 
between platelets and leucocytes, also involving endothelial cells, may represent a vicious circle 
playing a pathogenic role not only in the chronic atherosclerotic process, but also in the triggering
of ACS. 
4.10 Anti-inflammatory cytokines
A wide range of studies have established that CAD patients have increased levels of inflammatory 
cytokines, but less focus has been drawn to the importance of anti-inflammatory mediators. 
Among several anti-inflammatory mediators, IL-10 has been paid specially interest, and it has been 
showed that while unstable angina patients are characterized by markedly elevated plasma levels 
of inflammatory cytokines, no or only a modest increase in IL-10 levels has been reported in these 
patients96, 97, suggesting an inflammatory imbalance. Moreover, low IL-10 level in plasma has 
been found to be associated with poor clinical prognosis after ACS.98 IL-10 is a pleiotropic 
cytokine produced by T-cells, B cells, monocytes and macrophages, and it exhibits a variety of 
effect with relevance to atherogenesis such potent inhibition of various inflammatory cytokines, 
induction of anti-inflammatory mediators (e.g., IL-1 receptor antagonist and soluble TNF 
receptors), inhibition of MMP-9 combined with up-regulation of its endogenous tissue inhibitor 
(i.e., TIMP-1), down-regulation of TF expression in monocytes as well as anti-apoptotic effects on 
foam cells suggesting anti-atherogenic and plaque stabilizing effects.97, 99, 100 Moreover, studies in 
IL-10 transgenic and IL-10 deficient mice models have suggested an important role of this 
cytokine in both formation and stabilization of atherosclerotic lesions in vivo.101, 102 In fact, it has 
been proposed that IL-10 could be regarded as an immunological scalpel within the atherosclerotic 
vessel wall, being a mediator with therapeutic potential in atherosclerosis. 99, 103
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4.11 TGF-ȕ superfamily - pleitropic mediators with anti-inflammatory potential  
TGF-E and related cytokines is another group of mediators with potential anti-inflammatory and 
anti-atherogenic effects. Thus, Robertson et al. have shown that apoE–/– mice with abrogated TGF-
ß signaling in T cells developed dramatically accelerated atherosclerosis with a several-fold 
increase in lesion size as well as a more vulnerable lesion phenotype with reduced collagen and 
increased inflammation, further suggesting a protective role for this cytokine in atherogeneis.104
TGF-ȕ superfamily is a large family of structurally related polypeptides comprising more 
than 30 members. This family of growth and differentiation factors contains 3 subgroups; the 
prototypic TGF-ȕs, the activins and the bone morphological proteins (BMPs). They control 
cellular functions like proliferation, differentiation, adhesion and homeostasis by modifying 
specific sets of genes. The TGF- ȕ superfamily elicits its effect through serine/threonine receptors, 
classified as type I or II, leading to a subsequent phosphorylation and activation of specific 
intracellular mediators called Smads. Firstly, the receptor regulated Smads (R-Smads) are 
presented to the receptor complex by a binding protein called SARA or “Smad anchor for receptor 
activation” for a subsequent phosphorylation. Once phosphorylated, the R-Smads dissociate from 
both SARA and the receptor complex. Moreover, phosphorylated R-Smad recruit the co-Smad, 
Smad4, whereby the complex translocates from the cytoplasm to the nucleus where they bind 
directly to the DNA and thus control gene expression. These actions are opposed by the inhibitory 
I-Smads, Smad6 and Smad7, which form complexes with the activated receptors and thus prevent 
Smad phosphorylation and activation.105, 106
 The TGF-ȕ family contains unique and pleiotropic proteins exerting an array of functions. 
They are produced by and act on a wide range of cells, but depending on total cytokine milieu 
present and state of cell differentiation, they present dichotomous functions. Acting in both an 
autocrine and paracrine matter, they can both inhibit and stimulate the immunological response.107-
110 Administration of TGF-ȕ is shown to be beneficial in septic shock. In mice models, TGF-ȕ
producing cells protect against colitis in inflammatory bowel disease.111 Moreover, in TGF-ȕ null 
mice, loss of TGF-ȕ ligand results in progressive tissue inflammation and inflammatory disorders. 
On the other hand, TGF-ȕ induced deposition of extracellular matrix on site of injury can lead to 
scarring and fibrosis, the latter associated with chronic inflammatory disorders.112 Thus, lines of 
evidence couple TGF-ȕ to the pathogenesis of autoimmune and inflammatory disorders, though in 
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conflicting roles.113
The activins, a subgroup in the TGF-ȕ family, were initially discovered as inducers of 
follicle-stimulating hormone (FSH), but have shown to hold a wider range of functions concerning 
cell growth and development. In mice models they are found to play a role in tissue repair and 
inhibit proliferation of intestinal epithelium in inflammatory bowel disease.114 There are also some 
studies implicating activin A in the pathogenesis of rheumatoid arthritis and sepsis possibly 
mediating anti-inflammatory net effects, but the results are somewhat conflicting. Recent studies 
suggest that activin A could be involved in atherogenesis by inhibiting foam cell formation and 
inducing differentiation of neointimal SMC.115 Given its association with inflammatory disorders, 
potentially mediating anti-inflammatory effects, it is therefore tempting to hypothesize a potential 
attenuating role of activin A in atherogenesis and plaque destabilization.
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Figure 3. Overview of signal transduction in the TGF-ȕ superfamily.
Binding of ligands leads to the formation of a complex of receptor serine/threonine kinases (type I and II) and 
transphosphorylation of the type I receptor by the type II receptor. The activated type I receptors phophorylate 
receptor regulated Smads (R-Smads) which are presented to the receptor complex by a binding protein called SARA 
or “Smad anchor for receptor activation”. Once phosphorylated, the R-Smads dissociate from both SARA and the 
receptor complex. Moreover, phosphorylated R-Smad recruit the co-Smad Smad4, whereby the complex translocates 
from the cytoplasm to the nucleus where they bind directly to the DNA and regulate transcription through interaction 
and cooperation with transcription (Tx) factors and co-activators. Both the phosphorylation of R-Smads and the 
interaction between R-Smads and Smad 4 is inhibited by the inhibitory Smads, Smad6 or Smad7.  
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5. Purpose of the study 
In this thesis we attempted to further investigate the immunopathogenic mechanisms in CAD and 
plaque destabilization, particularly focusing on: 
a. The pathogenic role of chemokines. 
b. The pathogenic role platelet-mediated inflammation. 
c. The pathogenic role of activin A as a potential “new” anti-inflammatory mediator in this 
process.
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6. Summary of results 
Paper I: Potential Anti-Inflammatory Role of Activin A in Acute Coronary 
Syndromes.
The aim of the study was to investigate whether the TGF-E superfamily member activin A could 
play a role in the immunopathogenesis of acute coronary disease. 
x Patients with stable angina had raised activin A concentrations as assessed by protein levels 
in serum and mRNA levels in PBMC. 
x In contrast to several reports on inflammatory cytokines, activin A levels were equal 
(serum) or even lower (PBMC) in unstable angina as compared to those with stable disease. 
x In contrast to the enhanced expression of downstream activin A mediators (i.e., Smad3) in 
PBMC from stable angina patients as compared with healthy controls, no changes (i.e., 
Smad3) or even a down-regulation (Smad2) was seen in unstable disease. Likewise, the 
activin type II receptors, representing the primary ligand-binding protein, were down-
regulated in unstable as compared to stable disease. 
x Stable angina patients undergoing PCI showed a decrease in the activin A/follistatin ratio 
within 48 hours, suggesting down-regulatory effects on activin A activity during 
mechanically induced plaque rupture. 
x While activin A dose-dependently suppressed the release of inflammatory cytokines from 
PBMC in stable and unstable angina, an opposite effect was found in healthy controls.
Paper II: Platelet-derived LIGHT induces inflammatory responses in 
endothelial cells and monocytes. 
In paper II we sought to investigate whether the TNF superfamily member LIGHT was associated 
with platelets and if this cytokine could be involved in platelet-mediated inflammation.
x We found that platelet upon SFLLRN activation gradually released significantly amount of 
soluble LIGHT reaching a maximum after 120 minutes.  
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x The release of LIGHT involves GP IIb/IIIa-dependent mechanisms and action of metal-
dependent proteases as well as intracellular processes such as actin polymerization. 
x We also report that platelet-derived LIGHT is biologically active and can induce an 
inflammatory response in monocytes and particularly within endothelial cells measured as 
up-regulation of adhesion molecules E-selectin and VCAM-1 and release of the 
inflammatory chemokines IL-8 and MCP-1.  
x We demonstrated that thrombus material, obtained at the site of plaque rupture in STEMI 
patients, contains platelet-associated LIGHT. Moreover, PCI, representing a mechanically 
induced plaque rupture, significantly increased plasma levels of LIGHT in stable angina 
patients, further suggesting that LIGHT-mediated inflammation also is operating in vivo
within an inflamed and thrombotic vessel wall. 
Paper III: Increased levels of Neutrophil-activating peptide-2 in acute coronary 
syndromes. Possible role of platelet-mediated vascular inflammation. 
In this paper we investigated the role of the CXC chemokine neutrophil-activating peptide-2 (NAP-
2) in CAD. 
x Patients with stable and particularly those with unstable angina had markedly raised plasma 
levels of NAP-2 compared to controls, accompanied by increased expression of its receptor 
CXCR2 in monocytes. 
x Even though NAP-2 is considered to be a predominantly platelet-derived chemokine, we 
found that PBMC released large amounts of NAP-2 upon stimulation with 
phytohemagglutinin (PHA), lipopolysaccharide (LPS), and the thrombin receptor agonist 
SFLLRN, with a particularly prominent response in unstable angina.
x By immunostaining, we showed that NAP-2 protein was localized in macrophages and 
vascular SMC of atherosclerotic carotid plaques and in monocytes and platelets of coronary 
thrombi from STEMI patients.  
x In vitro, recombinant and platelet-derived NAP-2 increased the expression of adhesion 
molecules and chemokines in endothelial cells.  
x While aspirin reduced NAP-2, statin therapy increased plasma levels of this chemokine 
with stimulating effects both on platelets and leukocytes.
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Paper IV: Enhanced expression of the homeostatic chemokines CCL19 and 
CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in 
plaque destabilization.  
In this study we wanted to disclose any potential importance of the homeostatic chemokines 
CCL19 and CCL21 in CAD. 
x We detected increased plasma levels of CCL19 and CCL21 in CAD patients compared to 
healthy controls, accompanied by decreased expression of their corresponding receptor 
CCR7 in PBMC, with the most marked changes in those with unstable disease.
x In contrast to the decreased CCR7 expression in circulating T cells from CAD patients, 
strong CCR7 immunostaining was seen in T cells within the atherosclerotic lesions of the 
ApoE-/- mice and in human atherosclerotic carotid plaques, accompanied by strong 
immunoreactivity of CCL19/CCL21 in macrophages and SMC within the atherosclerotic 
lesions.
x In macrophages, inflammatory stimuli and oxLDL down-regulated and cAMP up-regulated 
CCR7 expression.
x CCL19 and CCL21 were shown to induce an inflammatory phenotype in T cells and 
macrophages and increased MMP and tissue factor (TF) levels in the latter cell type. 
x Aggressive statin therapy (i.e., atorvastatin 80 mg qd), but conventional statin therapy (i.e., 
simvastatin 20 mg qd), decreased plasma levels of CCL19/CCL21 levels and increased 
CCR7 expression in circulating CD4+CD3+ T cells in CAD patients.  
Paper V: Increased levels and inflammatory effects of soluble CXCL16 in 
coronary artery disease - down-regulatory effects of statins. 
The aim of this study was to elucidate the role of CXCL16 in CAD and study the ability of HMG-
CoA reductase inhibitors (statins) to modulate CXCL 16 levels.
x Patients with stable and unstable angina had raised plasma levels of CXCL16 compared to 
controls, with no differences between these two groups of patients. 
x Both conventional (simvastatin 20 mg qd) and aggressive (atorvastatin 80 mg qd) statin 
therapy significantly down-regulated plasma levels of CXCL16 during 6 months of 
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therapy.
x In vitro, atorvastatin significantly decreased the IL-1E-mediated release of CXCL16 from 
PBMC and endothelial cells.
x The attenuating effect of atorvastatin on the IL-1E-mediated release of CXCL16 in PBMC 
seems to involve inhibition of the protease ADAM10.  
x Soluble CXCL16 enhanced the secretory potential in vascular SMC by increasing the 
release of IL-8, MCP-1 and MMPs.  
x Soluble CXCL16 increased the release of IL-8 and MCP-1 in PBMC from healthy controls 
and particularly in cells from CAD patients.  
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7. Discussion 
7.1 Methodological considerations 
7.1.1 Individuals 
Patients with verified CAD, defined either as stable effort angina NYHA class II or III and a 
positive exercise test, or as unstable angina defined as ischemic chest pain at rest within the 
preceding 48 hours (i.e., Braunwald´s class IIIBa) and transient ST-T segment depression and/or 
T-wave inversion, were studied in this thesis. The diagnosis of CAD was confirmed in all patients 
by coronary angiography showing at least 1 vessel disease (>50% narrowing of luminal diameter). 
According to standard procedures, the UAP patients had received heparin or low-molecular weight 
heparin before inclusion, but this medication had been discontinue >12 hours before blood 
sampling. Nevertheless, heparin therapy may influence the plasma/serum levels of cytokines and 
chemokines.116
To minimize confounding factors known to modulate inflammatory responses, only 
verified CAD patients without concomitant disease such as congestive heart failure, infections, 
lung diseases, cancers or autoimmune diseases were included in the studies. 
7.1.2 Blood sampling and chemokine measuring in blood and cell culture supernatants 
One of the main purposes of this thesis was to study cytokine levels in plasma/serum, mononuclear 
cells and platelets, obtained from CAD patients and healthy controls. Several factors related to 
blood collection and preparation of samples may influence the measured cytokine levels in 
plasma/serum and cells. First, contamination of collection tubes, buffers and media with 
endotoxins and microorganisms may activate the cells and induce inflammatory reactions.117, 118
For in vitro studies, endotoxin levels were tested in all media, buffers and stimulant preparations 
used (all<10pg/mL). Second, time before storage, temperature during storage and freeze and thaw 
cycles may also influence cytokine levels.119, 120 Therefore, in our experiments blood samples were 
immediately immersed on ice before processing, sera were kept frozen at -80°C, and thawed less 
than three times. Third, it has been reported that the recovery of cytokines from blood samples 
might be more optimal from plasma than from serum, and that EDTA should be preferred as an 
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anticoagulant as it seems to inhibit ex vivo cytokine production during plasma preparation.121
Finally, in order to perform blood sampling in a way that ensured intact, non-activated platelets 
which at a later stage were able to respond to agonist stimulation, we used citrate as an 
anticoagulant which binds Ca2+ at a level that avoids plasma coagulation but allows platelet 
activation and aggregation due to agonist stimulation. It has been reported that citrated plasma with 
addition of the anti-platelet agent theophyllin, adenosine and dipyridamol (CTAD plasma) which 
may cause less degree of ex vivo platelet activation compared to citrated plasma alone, and would 
probably be a better alternative.122 However, we did not experience problems with ex vivo platelet 
activation observed as minimal to non P-selectin expression and absent aggregation in samples 
with untreated patients. 
7.1.3 Enzyme Linked Immunosorbent Assays (ELISAs) 
Commercially available ELISAs were used for measuring the protein levels of cytokines in this 
study. The ELISA technique is based on the antibody sandwich principle, where a capture 
antibody specific to the protein of interest is bound to a microtiter plate to create a solid phase. 
After addition of the samples and standards, a second enzyme-conjugated detection antibody binds 
to a different epitope of the molecule being measured, completing the sandwich. The addition of a 
detection reagent (e.g., streptavidin-horseradish peroxidase) and a substrate solution (e.g., 
tatramethylbenzidine/hydrogen peroxide) leads to the development of color proportional to the 
amount of protein measured.  
ELISAs are widely used as they are easy, time sparing and specific. However, some 
important limitations should be mentioned. First, the unique recognition profile of the antibodies 
will differ between kits from different manufacturers, making comparisons of results unreliable. 
Second, the presence of soluble cytokine receptors, cytokine antibodies and binding proteins in 
biological samples may affect the measured cytokine levels.123 In the present study kits from the 
same manufacturer was used to be able to compare the results obtained. In most cases, compared 
data (e.g., patients versus controls) were run on the same microtiter plate to minimize run-to-run 
variability.
7.1.4 Analysis of gene expression 
RNA was isolated using silica-gel based membranes (RNeasy columns), guanidium thiocynate-
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phenol-cloroform as well as use of paramagnetic beads and the MagnaPure LC Robot. Notably, no 
comparisons were made between RNA extracted by different methods. All RNA samples were 
treated with DNase I to eliminate contamination of small amounts of DNA. RNA concentration 
and purity was evaluated by measuring the absorbency at 260/280 mm using a spectrophotometer. 
Only samples with high integrity and purity were used in our experiments (absorbance ratio >1.8).
 To analyze the gene expression of specific transcripts we used real-time RT-PCR. Real-
time RT-PCR is the most sensitive and time-saving method for detection of low-abundance 
mRNA. To correct for sample-to-sample variations, normalization of gene expression is performed 
against house-keeping (control) genes, the most commonly used being glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH), ȕ-actin and 18S ribosomal RNA.124  The control genes 
should ideally not be subject for any regulation in the tissue or cells investigated. In our 
experiments, house-keeping genes and the relative expression of these were stable between 
samples within the same experiment. 
7.1.5 Cell isolation and culture 
In this thesis several cellular experiments were performed, including studies in PBMC, HUVEC, 
vascular SMC, platelets and THP-1 macrophages. There is always a danger of unwanted ex vivo
activation of cells during isolation procedures. Differences in blood sampling techniques or cell 
separation may be considered as important non-physiological ex vivo induction of cytokines. 
Accelerated blood flow during blood sampling and isolation of PBMC by density gradient 
centrifugation over Ficoll-Hypaque has been shown to induce up-regulation of the mRNA levels of 
several cytokines.125 Accordingly, in this thesis a standardization of blood sampling and cell 
isolatiotion procedures was used in all experiments examining PBMC. After isolation the cells 
were immediately stored in liquid nitrogen (freshly isolated PBMC for gene analyses or used 
directly in cell cultures). Second, spontaneous activation of PBMC during culturing is well known, 
and monocytes appear to be the most sensible because of plastic adherence induced activation.126
Third, platelets may  easily become activated during isolation procedures.127 In our experiments 
platelets were kept and cultured in autologous plasma (PRP), avoiding several centrifugation and 
resuspension steps compared with cultured in buffer. Finally, in all experiments involving cells, 
the results were compared when they were obtained during the same experiments, when the 
experiments had been run in parallel or when they involved paired observation of the same 
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patients, minimizing differences and misinterpretation of results due to ex vivo activation of cells. 
However, although ex vivo activation may contribute to enhanced chemokine mRNA and protein 
levels in several cell types, we believe that the differences between CAD patients and controls may 
be rather underestimated than overestimated in our experiments. It is also conceivable that inactive 
cells from healthy controls more easily become activated ex vivo than cells from patients already 
activated in vivo.128
7.2 Chemokines and atherogenesis 
7.2.1 NAP-2: another CXCR2 ligand that is involved in atherogenesis and plaque 
destabilization 
Chemokines are thought to be important actors in the inflammatory process characterizing 
atherogenesis and plaque destabilization. Thus, enhanced expression of various chemokines such 
as IL-8 and MCP-1 has been found within atherosclerotic plaques in humans, and targeted
disruption of the genes for MCP-1, CCR2 (i.e., MCP-1 receptor), and CXCR2, which binds IL-8, 
significantly decrease atherosclerotic lesion formation in mice prone to develop atherosclerosis.53-
55 Moreover, some studies in mice models suggest that also other CXCR2 ligands (i.e., GRO-Į)
could be involved in atherogenesis at least partly by promoting monocyte arrest in inflamed 
endothelium.129 However, while there are several reports on IL-8 in human CAD, few studies have 
examined the role of other CXCR2 ligands in human atherosclerotic disorders.  
 In paper III we report increased NAP-2 levels in angina patients with particularly high 
levels in those with unstable disease, accompanied by increased expression of its corresponding 
receptors (i.e., CXCR1 and CXCR2) on circulating monocytes. The relationship between raised 
NAP-2 levels and unstable disease was further supported by our immunohistochemical analyses 
showing strong NAP-2 immunostaining on platelets and monocytes/macrophages within thrombus 
material obtained at the site of plaque rupture in patients with STEMI undergoing PCI as well as in 
macrophages and SMC within symptomatic atherosclerotic carotid plaques. Our findings in paper 
III suggest that NAP-2 should be added to the list of CXCR2 ligands that could be involved in 
atherogenesis and plaque destabilization.
Chemokines can be produced by a variety of cells including leukocytes and endothelial 
cells, and recent studies suggest that also platelets contain a number of these chemotactic cytokines 
stored in their Į-granules. Hence, upon activation, platelets release significant amounts of various 
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chemokines such as RANTES and PF4, promoting inflammation in adjacent leukocytes and 
endothelial cells.76 Activated platelets also release large quantities of NAP-2 through proteolytic 
conversion from its precursors E-TG and connective tissue-activating proteinIII (CTAP III). 
Indeed, in paper III we show that platelets upon SFLLRN activation release large amount of NAP-
2 in both angina patients and healthy controls. Among the chemokines stored and secreted by 
platelets, CXCL7 is the most abundant representative. In fact, by appearing in the serum at 
micromolar concentrations (1.6 to 4.8 ȝȂ), CXCL7 surpasses most other platelet-associated 
chemokines up to several orders of magnitude. CXCL7 consists of several molecular variants that 
differ in the length of their N-terminus such as b-TG, platelet basic protein (PBP), CTAPIII, and 
NAP-2, representing a highly inflammatory end product of CXCL7 proteolysis after platelet 
activation.93 Although the actual ELISA used in paper III can not fully differ NAP-2 from other 
CXCL7 molecular variants, our finding strongly indicate enhanced levels of NAP-2 in CAD, 
representing an end-product of CXCL7 degradation and activation.
Though originally described as solely a platelet-derived chemokine, Waltz et al. detected 
NAP-2 in monocyte cultures after stimulation with LPS.130 Recently, NAP-2 was found to be 
expressed in macrophages within advanced carotid atherosclerotic plaques.131 In the present study, 
we extend these findings by showing that PBMC, THP-1 macrophages, and vascular SMC release 
NAP-2 upon various stimuli such as oxLDL and LPS, and notably, the release of NAP-2 from 
PBMC was particularly enhanced in cells from unstable angina patients further underscoring that 
NAP-2 is activated during unstable disease. Leukocyte-derived proteases have the capacity to 
cleave PBP and CTAP-III behind the single tyrosine residue present in CXCL7.93 Although we 
cannot at present determine whether the elevated NAP-2 release in PBMC reflects increased 
synthesis or enhanced generation of NAP-2 from its precursors (i.e., enhanced protease activity) or 
both, our data clearly shows the ability of other cells than platelets to generate NAP-2. Moreover, 
an increase in NAP-2 was also seen at the mRNA level, suggesting that PBMC have the ability to 
produce NAP-2. Our finding of NAP-2 protein in macrophages and SMC within atherosclerotic 
carotid plaques and in monocytes of thrombus material obtained from the site of plaque rupture 
during MI, further support that these cells have the capacity to express NAP-2 and demonstrate 
that they do so in atherothrombosis.  
NAP-2 virtually represents the only CXCL7 protein that may be addressed as a functionally 
typical chemokine, since it is the only variant capable of efficiently stimulating chemotactic 
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migration and thereby recruitment to inflammatory sites of its target cells. With regard to this, PBP 
and CTAPIII may be addressed as inactive precursors of NAP-2, although they exhibit a variety of 
other biological functions independently of proteolytical processing (e.g., effects on glucose 
metabolism and fibroblast mitogenic activity). In contrast, several studies support inflammatory 
effects of NAP-2 promoting recruitment and activation of granulocytes into inflamed tissue.132
However, while most previous studies have focused on the effect of NAP-2 on granulocytes, we 
show in paper III that NAP-2 is a potent inducer of the adhesion molecules E-selectin and VCAM-
1 as well as the chemokines MCP-1 and IL-8 in endothelial cells. This effect was induced not only 
by recombinant human (rh)NAP-2, but also by platelet-derived NAP-2. Furthermore, we found 
that monocytes from unstable angina patients showed enhanced chemotactic responses to NAP-2, 
suggesting that the increased CXCR2 expression in monocytes from these patients affects their 
functional responses. Previously, NAP-2 has been shown to promote monocyte arrest on inflamed 
endothelium under flow conditions, further supporting a role for NAP-2 in vascular inflammation. 
 NAP-2 binds to both CXCR1 (low-affinity) and CXCR2 (high-affinity). Although the 
ability of NAP-2 to function as an agonist for CXCR1, recent reports suggest that NAP-2 may 
address its two receptors in sequence and continue cell attraction through CXCR1 at high 
concentrations where CXCR2 has already undergone desensitization.133 In paper III we found that 
neutralizing antibodies against CXCR1 and CXCR2 attenuated the NAP-2-induced increase in IL-
8 and MCP-1 levels in HUVEC supernatants by 41% and 43%, respectively, indicating that this 
NAP-2-mediated effect involves ligation of both receptors. Nevertheless, although the exact 
mechanisms of action will have to be further investigated, our findings in paper III suggest that 
NAP-2 has the potential to induce an inflammatory response within the atherosclerotic plaque, and 
by its ability to promote leukocyte activation as well as expression of chemokines and adhesion 
molecules within the vessel wall, such a NAP-2-driven inflammation could ultimately lead to 
plaque rupture and acute coronary syndromes. Based on the high levels of NAP-2 in serum/plasma 
as well in the microenvironment within the atherosclerotic lesion, consisting of highly activated 
platelets and macrophages, both being relevant cellular sources of NAP-2, such NAP-2-mediated 
inflammation could clearly be of relevance also in vivo in CAD patients.
7.2.2 CXCL16: a transmembrane chemokine with pro-atherogenic properties  
Chemokines expressed in inflammatory conditions were known to be secreted as soluble 
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molecules.50 With the discovery of CX3CL1 and CXCL16, which are synthesized as 
transmembrane molecules and transported to the cell surface, this theory was abandoned.134, 135
The scavenger receptor for phosphatidylserine and oxLDL (SR-PSOX) is a recently discovered 
macrophage receptor that mediates internalization of oxLDL and phosphatidylserine-coated 
particles such as apoptotic bodies.136 Surprisingly, the sequence of SR-PSOX was found to be 
identical to the recently discovered chemokine, CXCL16. Along with these findings, its T cell 
expressed receptor, CXCR6 was discovered.135 Moreover, CXCL16 was detected in macrophages 
in vitro and atherosclerotic lesions in vivo.136-138 Hofnagel et al.139 detected CXCL16 in cultured 
vascular SMC, cells that have later been shown also to express CXCR6. CXCL16 is the only 
known transmembrane CXC chemokine, existing in membrane-bound and soluble forms, and it 
fulfills functions of a T cell chemoattractant140, a scavenger receptor for oxLDL as well as an 
adhesion molecule.135, 136, 138, 141 Although this involvement in both inflammation and lipid 
metabolism could indicate a role in atherosclerosis, its role in atherosclerotic disorders is debated.  
Increased levels of soluble CXCL16 have been reported in various inflammatory conditions 
such as rheumatoid arthritis and systemic lupus erythematosus.142-144 It seems that cleavage of 
transmembrane chemokines is associated with the inflammatory cascade and, therefore, the soluble 
form of CXCL16 may serve as a stable marker of inflammation.49 However, conflicting data exist 
on plasma levels of CXCL16 in CAD. While Sheikine found decreased plasma levels of CXCL16 
in both stable and unstable angina145, Lehrke reported increased plasma levels of this chemokine in 
a large population of CAD patients, particularly in those with unstable disease.146 In paper V we 
report increased plasma levels of CXCL16 in CAD patients independent of co-morbidity such as 
diabetes and hypertension. The reasons for these discrepancies are at present not clear but could 
involve differences in blood sampling and storage protocols and differences in patient (e.g., 
different degree instability) and control characteristics. Nevertheless, Wuttge et al. have recently 
demonstrated increased expression of CXCL16 and CXCR6 in atherosclerotic plaques from 
humans and apolipoprotein-E-deficient mice.138 Taken together, these data suggest increased 
expression of CXCL16 in human and murine atherosclerotic disease, both in circulation and within 
the atherosclerotic lesion.  
The duality of CXCL16, existing in membrane bound and soluble forms, enables CXCL16 
to both promote binding and adhesion of lymphocytes, oxLDL, and bacteria, as well as acting as a 
classical chemoattractant towards different leukocyte subsets, reflecting that the membrane-bound 
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and soluble form of CXCL16 possesses different biological functions.140, 49 Much focus has been 
drawn against the function of the transmembrane form. However, while membrane-bound 
CXCL16, expressed on endothelial cells and macrophages within the vessel wall, has been linked 
to vascular inflammation by its ability to promote binding and adhesion of lymphocytes, soluble 
CXCL16 may also promote inflammatory responses, acting as a classical chemoattractant against 
various lymphocyte subsets.49 Moreover, there are also some reports suggesting that soluble 
CXCL16 may have functions beyond that of leukocyte recruitment.147, 148 Hence, CXCL16 has 
been found to enhance the activity of antigen-presenting cells involving toll-like receptor (TLR)9-
related mechanisms.149 Soluble CXCL16 has also been shown to promote SMC proliferation.150
Herein we report that CXCL16-activated vascular SMC release inflammatory chemokines and 
MMPs, suggesting that CXCL16 may transform these cells from a contractile to a 
proliferative/secretory phenotype which is a hallmark of the vascular remodeling characterizing 
atherogenesis. Moreover, we found that soluble CXCL16 promoted IL-8 and MCP-1 release in 
PBMC, with a particularly marked response in CAD patients, further underscoring the relevance of 
CXCL16-mediated inflammation in atherogenesis. One might argue that the concentration of 
CXCL16 used in the in vitro experiments is not relevant to the in vivo situation. However, it is not 
inconceivable that similar concentrations may be found in the inflammatory microenvironment 
within an atherosclerotic plaque, consisting of several types of CXCL16 secreting cells (e.g., 
macrophages, SMC, and endothelial cells). The combination of CXCL16 with several other 
inflammatory cytokines operating within the atherosclerotic lesion may further enhance its 
inflammatory potential. Thus, based on our data in paper V, it is tempting to hypothesize that 
CXCL16 is not only a marker but also a mediator of inflammation in CAD patients 
CXCL16 has been shown to be up-regulated in atherosclerotic plaques by the pro-
atherogenic cytokine IFN-Ȗ, potentially acting in a positive feedback loop to increase inflammation 
in the atherosclerotic lesion.138 CXCL16 seems also to be mediator of the pro-atherogenic effects 
of IL-18. Since CXCL16 are induced by the Th1 master cytokine IFN-Ȗ and preferentially act on 
Th1 cell subsets compared with Th2 cells, it has been suggested to further enhance Th1-associated 
inflammatory responses with potential pro-atherogenic consequences. In contrast to these findings, 
as well as our data in paper V, a recent murine study suggests that targeted disruption of CXCL16 
accelerates atherosclerosis accompanied by increases macrophage recruitment to the aortic arch 
and elevated MCP-1 and TNF-Į mRNA levels.151 However, as the membrane-bound and soluble 
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form of CXCL16 seem to have different biological function, enhanced atherogenesis in CXCL16 
knock-out mice may not necessarily argue against a pro-atherogenic effect of soluble CXCL16. In
vitro, macrophages from CXCL16-deficient mice display reduced capacity to bind and internalize 
oxLDL. However, while this scavenger receptor function may account for the atheroprotective role 
of CXCL16, the inflammatory properties of CXCL16, and in particular of the soluble form lacking 
the ability to bind oxLDL, may counteract this beneficial effect. Also, substantial evidence 
indicates that CXCL16 may have constitutive functions such as promotion of cell survival and 
normal leukocyte recruitment. In the liver CXCL16/CXCR6 interaction confers to survival of 
patrolling NKT cells.152 CXCL16 is also expressed by epithelial cells associated with gut 
lymphatics, where it may be involved in constitutive homing and positioning of T cells in the 
absence of inflammation.153 Thus, while too much CXCL16 may be harmful, too little may not 
necessarily be beneficial. Interestingly, it has recently been shown that blocking CXCL16 actions 
by anti-sera limits the progression of glomerulonephritis154, supporting a role for CXCL16 as a 
target for anti-inflammatory therapy. However, future studies will have to more precisely define 
the inflammatory and constitutive functions of CXCL16 as well as clarify the different effects of 
the membrane-bound as opposed to the soluble form of CXCL16 in inflammation.  
Anti-TNF therapy142 and the peroxisome proliferator-activated receptor-Ȗ agonist 
pioglitazone146 have previously been found to down-regulate serum levels of CXCL16 in patients 
with rheumatoid arthritis and metabolic syndrome, respectively. In paper V we show that statin 
therapy significantly reduces plasma levels of CXCL16 in CAD patients, independently of 
cholesterol lowering. Moreover, in vitro experiments showed the ability of atorvastatin to attenuate 
the release of CXCL16 in IL-1-activated endothelial cells and PBMC further supporting such a 
notion. CXCL16 is synthesized as a transmembrane molecule and transported to the cell surface. 
To date, no evidence that this form arise from differential splicing has been provided. Instead, the 
conversion of transmembrane into soluble CXCL16 has been attributed to a metalloproteolytic 
process. This cleavage can occur at the cell surface but it cannot be excluded that both chemokines 
are also cleaved in intracellular compartments. ADAM10 has been found to be a major regulator of 
CXCL16 shedding from its membrane-bound form.146, 155 Our finding in paper V may suggest that 
atorvastatin attenuates the release of CXCL16 from PBMC by inhibiting ADAM10. Increased 
ADAM10 activity, resulting in increased release of soluble CXCL16 from the cell surface has been 
shown to be accompanied by down-regulation of the transmembrane CXCL16 form. However, in 
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paper V we found that the inhibition of CXCL16 release, most probably as a result of attenuated 
ADAM10 activity, was not associated with increased expression of CXCL16 on the cell surface. 
Although an atorvastatin-mediated inhibition of CXCL16 cleavage in intracellular compartments 
remain a potential explanation49, these issues will have to be further investigated in forthcoming 
studies. Nevertheless, our findings further support the notion that statins possess anti-inflammatory 
properties partly independent of its lipid lowering effects. However, although ~80% of the angina 
patients used statins, they still had significantly raised plasma levels of CXCL16. Moreover, in 
paper III we showed that both aggressive (i.e., atorvastatin 80 mg qd) and conventional (simvastain 
20 mg qd) significantly enhanced plasma levels of NAP-2 in CAD patients after 6 months of 
therapy, and such inflammatory effects of statins have also been reported by others.156 Although 
we clearly do not argue against a beneficial role for statins in atherosclerotic disorders, these 
results suggest that other medication with another anti-inflammatory profile could also be of 
interest in these disorders.
7.2.3 CCL19 and CCL21: Inflammatory effects of homeostatic chemokines in CAD 
In contrast to the above mentioned inflammatory chemokines, the homeostatic CCL19 and CCL21 
are constitutively expressed within lymphoid tissues, and involved in maintaining homeostatic 
leukocyte trafficking and cell compartmentalization within these organs.157 Secondary lymphoid 
organs orchestrate immune responses by optimizing encounters of lymphocytes with APC such as 
DC.158, 159 The control of DC migration is pivotal for the initiation of cellular immune responses. 
DCs are professional APCs who reside in the periphery in an immature state. When activated with 
inflammatory stimuli, they undergo phenotypical and functional changes, including up-regulation 
of the chemokine receptor CCR7.160 Activated DCs then home to the lymphoid organs, a migration 
governed with high precision by the chemokines CCL19 and CCL21, the two ligands for CCR7.161, 
162 Naive or memory T cells enter the lymph node using the same receptors. Once inside the lymph 
node, CCR7+ DCs and T cells follow gradients of CCL19 and CCL21 in T cell zones to find one 
another. Thus, CCR7 and its ligands link innate and adaptive immunity through their effects on 
interactions between T cells and DCs.
 In addition to their role in leukocyte and DC migration, recent studies have implied a 
potential role of CCL19/CCL21 in regulation of their immunological potential, possibly promoting 
inflammatory responses.163, 164 CCL21 was also found to induce de novo formation of lymph node-
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like structures with infiltration of lymphocytes in non-lymphoid tissue, further underscoring their 
inflammatory potential.43, 44 Moreover, CCL19/CCL21/CCR7 have been implicated in the 
pathogenesis of various autoimmune and inflammatory disorders such as rheumatoid arthritis, 
diabetes mellitus, and inflammatory bowel disease.44, 165, 166
 Based on their role in T cell homing into non-lymphoid tissue, which potentially could be 
an atherosclerotic plaque, along with their newly discovered involvement in inflammation, we in 
paper IV wanted to disclose a possible role of CCL19 and CCL21 as well as their common 
receptor CCR7 in CAD. By combining different approaches including clinical studies in CAD 
patients, in vitro studies, and in vivo experiments in ApoE-/- mice, we found an implication of these 
chemokines in CAD. We demonstrated increased CCL19/CCL21 expression in mouse and human 
atherosclerotic lesions as well as in plasma of CAD patients with particularly high levels in those 
with unstable disease. Interestingly, enhanced expression of the corresponding receptor CCR7 was 
detected in atherosclerotic plaque T cells, whereas circulating T cells from angina patients showed 
decreased CCR7 expression, primarily reflecting a down regulation in the percentage of 
CCR7+CD4+ T cells,. Although several non-mutually exclusive mechanisms may explain this 
phenomenon, we hypothesize that this pattern at least partly reflects a distribution of CCR7 
positive T cells from peripheral blood to the inflamed atherosclerotic lesions during plaque 
progression. However, several issues will have to be further clarified in forthcoming studies. It has 
been suggested previously that the CCR7- T cell subset defines an antigen-experienced, tissue-
homing (not lymph-node homing) memory T cell population with reduced proliferative 
capacity.167 These T cells have been termed effector-memory T cells, as increased effector 
functions have also been described in CCR7- T cells, such as a strong expression of IFN-Ȗ,
perforin, and granzyme A.168 Thus, it is possible that the decreased proportion of CCR7 negative T 
cells in peripheral blood in CAD may not necessarily be benificial, but rather represent a systemic 
inflammatory T cell phenotype. The recent observation that CCR7 is of importance for the 
function of regulatory T cells further support such a notion.
While we found no CCR7 expression in freshly isolated monocytes, THP-1 macrophages 
showed increased CCR7 expression. In paper IV we also showed that cAMP further enhances this 
up-regulation of CCR7 expression during macrophage differentiation. E-adrenergic receptor 
activation is an important stimulus for elevation of intracellular cAMP levels, and as CAD patients 
are known to have persistently increased catecholamine levels169, this finding could be of 
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relevance also in relation to CAD. In fact, we found a CCR7-inducing effect in monocytes of the 
E-adrenergic receptor agonist isoproterenol, further supporting such a notion. Our findings could 
suggest an up till now unrecognized immunomodulatory potential of E-adrenergic receptor 
blockers, but if such mechanisms are operating in vivo in CAD patients with persistently activation 
of both the immune and the E-adrenergic systems and with desensitizing of the E-adrenergic
receptors are far from clear. In contrast to the cAMP elevating agents, various inflammatory 
stimuli (i.e., TNFD as well as TLR2 and TLR4 agonists) down-regulated CCR7 expression in the 
early phase of macrophage differentiation although the effect of LPS was rather modest. These 
data illustrate the complex regulation of CCR7 expression in macrophages within an inflammatory 
lesion such as an atherosclerotic plaque, being exposed to both down-regulatory (i.e., some 
inflammatory stimuli as well as oxLDL) and enhancing (i.e., cAMP elevating agents such as 
prostaglandin E2, which is abundant within atherosclerotic lesion, as well as an increased E-
adrenergic tone). These counteracting effects on CCR7 expression in macrophages that may be 
operating within an inflammatory atheroclerotic lesions could perhaps explain the rather weak 
CCR7 immunostaining in macrophages within human atherosclerotic carotid plaques. In contrast 
to the effect on CCR7 expression in macrophages, cAMP elevating agents had no effects on CCR7 
expression in T cells, further underscoring that the effect of the cAMP/protein kinase A type I 
system at least partly may differ between different cell types. Nevertheless, our data in paper IV 
illustrate the complex regulation of CCR7 expression during inflammation.  
 In addition to their ability to initiate and stimulate primary immune responses, CCL19 and 
CCl21 have recently been found to possess inflammatory properties as potent inducers of pro-
inflammatory cytokines in DC supernatants with a secondary promotion of a Th1-like phenotype 
in adjacent T-cells.164 Herein we show that CCL19 and particularly CCL21 induce inflammatory 
responses not only in T cells, but also in THP-1 macrophages by promoting the release of 
inflammatory cytokines. Moreover, and with relevance to plaque destabilization and thrombus 
formation, both CCL19 and CCL21 increased MMP activity and TF levels in THP-1 macrophages. 
If such mechanisms also are operating within the atherosclerotic lesion, they may in addition to 
promote an inflammatory Th1 phenotype, also induce a matrix degrading, inflammatory, and pro-
thrombotic phenotype in CCR7 expressing macrophages. Based on the high levels of 
CCL19/CCL21 in angina patients, with particularly high levels in unstable disease, as well as the 
increased expression of these molecules in symptomatic human carotid plaques, these mediators 
46
could potentially contribute to atherogenesis and plaque destabilization with subsequent thrombus 
formation and development of acute ischemic events. In fact, it is tempting to hypothesize that the 
combined feature of increased proportion of effector memory T cells in peripheral blood and 
increased interaction between CCL19/CCL21 and CCR7 expressing macrophages within the 
atherosclerotic lesion may result in both systemic and local inflammation in CAD. Two recent 
studies studies further support a role for CCL19/CCL21/CCR7 interaction in atherogenesis. First, 
Erbel et al. demonstrated that plaque tissues from patients with ischemic complications contained 
elevated levels of CCL19 and CCL21 primarily reflecting enhanced activation of dendritic cells 
within the atherosclerotic lesions.170 Second, Trogan et al. showed that blocking experiments with 
neutralizing antibodies to CCL19 and CCL21 revealed that CCR7 was functionally required for 
plaque regression in apoE-deficient mice.171
 Several clinical and experimental data indicate beneficial statin effects in addition to the 
lipid lowering activity particularly involving the inflammatory arm of atherogenesis.172, 173 In line 
with the findings in paper V (i.e., CXL16), but in contrast to our finding in paper III showing up-
regulation of NAP-2, such anti-inflammatory effects was also demonstrated in paper IV. However, 
whereas both aggressive (i.e., atorvastatin 80 mg qd) and conventional (simvastain 20 mg qd) 
significantly attenuated plasma levels of CXCL16 (paper V), only aggressive atorvastatin therapy 
significantly down-regulated plasma levels of CCL19/CCL21 and up-regulated CCR7 expression 
in PBMC, primarily reflecting an increase in CCR7+ CD4+ T cells. Whether this reflects a 
redistribution of T-cells from the atherosclerotic lesions to the circulation remains unclear. 
Whether this observation reflects redistribution from the inflamed atherosclerotic lesions to the 
circulation is at present not clear. However, two very recent papers have suggested that CCR7 may 
play an important role in emigration of T-cells from inflamed tissue with particularly pronounced 
effect on mobilization of the CCR7+CD4+ T-cells.174, 175 Moreover, Yilmaz et al. have recently 
showed that statin pre-incubated dendritic cells exhibited an immature phenotype with a 
significantly lower expression of CCR7, suggesting that these medications also could modulate 
CCR7 expression in macrophages within the plaque.176 Moreover, if the different effects of low 
dose simvastain and high dose atorvastain on CCL19/CCL21/CCR7 expression reflect drug- or 
dose-dependent differences or both should be further investigated. Nevertheless, some recent 
studies suggest that an intensive lipid-lowering statin regimen provides greater protection against 
cardiovascular events than does a standard regimen177, and it is possible that the superiority of 
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high-dose atorvastain also involves more potent immunomodulatory effects of this medication. 
Future studies should also investigate if the anti-inflammatory potential differs between lipophilic 
and hydrophilic statins. 
7.3 LIGHT: a “new” platelet-derived mediator of inflammation 
Beyond the traditional role of platelets as mediators of haemostasis and thrombus formation, 
increasing evidence now suggests that activated platelets play a key role in inflammation. Hence, 
upon activation platelets release and express inflammatory mediators, induce an inflammatory 
response in adjacent leukocytes and endothelial cells, and respond with activation to several of the 
mediators produced by these cells. Such interactions between platelets and leukocytes/endothelial 
cells seem to play a pathogenic role in atherosclerosis as well as in other immune-mediated
disorders. Platelets have upon activation been shown to secrete a number of inflammatory meditors 
such as PF-4, ȕ-TG, RANTES, and GRO-Į.64, 72-74 Recently, much attention has been focused on 
the role of platelet-associated CD40L, a ligand in the TNF superfamily, in this inflammatory loop 
between platelets and other cells 64, 178, and these cells have also been shown to express TNF-
related apoptosis-inducing ligand (TRAIL).89 In paper II we identified Lymphotoxins, exhibits 
Inducible expression, and competes with herpes simplex virus (HSV) Glycoprotein for Herpes 
virus entry mediator (HVEM/TR2), a receptor expressed by T lymphytes (LIGHT), another 
member of the TNF superfamily, as a potential important mediator of platelet-mediated 
inflammation.  
LIGHT signals through two different receptors; Herpes virus entry mediator (HVEM) and 
lymphotoxinE receptor (LTER). Studies in animal models suggest that LIGHT signaling pathways 
may be crucial for the development of various autoimmune disorders such as inflammatory bowel 
disease, nephritis, diabetes mellitus, and arthritis through effects on T cells and T cell homing.179-
181 While several studies have examined the pathogenic role of LIGHT in a variety of animal 
models182, 183, there are few reports on the role of this cytokine in human disorders. However, 
enhanced LIGHT expression has recently been detected in human atherosclerotic plaques184, and 
our group has shown elevated plasma levels of LIGHT in CAD patients with particularly high 
levels in those with unstable disease.185 In paper II we found increased plasma levels of LIGHT in 
CAD patients undergoing PCI, a human in vivo model for mechanical induced plaque rupture, as 
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well as in thrombus material obtained at the site of plaque rupture in patients with acute MI. These 
finding suggest the involvement of LIGHT in atherogenesis and plaque destabilization in human.  
LIGHT is expressed by activated T cells, monocytes, granulocytes, and immature dendritic 
cells, but until the present paper (paper II), it has not been identified in platelets. In paper II we 
demonstrated that LIGHT is secreted from platelets upon activation. In contrast to the rapid release 
of D-granule contents, activated platelets release LIGHT in a gradual and long-lasting manner, 
displaying a similar pattern as previously has been described for platelet-release of sCD40L.89-91
As for the mechanism of LIGHT-release from platelets, our findings in paper II suggest that the 
GPIIb/IIIa complex is important for this process. Thus, Glanzman thromasthenia platelets and 
normal platelets treated with a fibrinogen-blocking GPIIb/IIIa antagonist, and thereby inhibiting 
platelet aggregation90, showed markedly reduced activation-dependent LIGHT release. A similar 
pattern was also seen during GPIIb/IIIa inhibitory therapy in vivo, with a decrease in SFLLRN-
mediated LIGHT-release ex vivo in PRP from unstabile angina patients receiving GPIIb/IIIa 
antagonist therapy as compared with those who did not (paper II). These findings may indicate that 
maximal release of LIGHT requires cell-to-cell contact and that this is prevented in Glanzman 
thromasthenia and in the presence of GPIIb/IIIa antagonists, or that an outside-in signaling due to 
binding of fibrinogen to the activated GPIIb/IIIa complex may be important in this respect. 
Cytochalasin D, which is known to inhibit actin polymerization and disrupt actin filaments, and 
therefore affect endocytotic and exocytotic transport processes, reduced the release of LIGHT from 
activated platelets. Further, the MMP inhibitor GM6001, which potentially can act both 
intracellularly and on the outer platelet membrane, and EDTA, which may neutralize metal-
dependent enzymes on the outer membrane, both reduced the release of LIGHT from activated 
platelets (paper II). These results may implicate intracellular structures and reactions to be 
important for the release of LIGHT, and suggest that LIGHT, at least partly, is released from the 
platelets due to the actions of metal-dependent enzymes. Although the release of sCD40L and 
LIGHT during platelet activation show a similar long-lasting pattern as opposed to the rapid 
release (i.e., within 10 minutes after stimulation), differences between these TNF superfamily 
ligands may also exist. Thus, while platelet-bound CD40 seems to be involved in the regulation of 
sCD40L release, this seems not to be the case for the corresponding LIGHT receptors (i.e., HVEM 
and LTER). Moreover, our group has recently showed that these ligands respond differently to 
prostacyclin therapy in vivo (Otterdal K, Aukrust P, Damås JK, unpublished data).  
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It has been shown that soluble LIGHT induces increased IL-8 secretion and growth arrest 
in melanoma cells186, and Anand et al. showed that soluble LIGHT plays an important role in the 
pathogenesis of liver inflammation.187 These findings indicate that soluble LIGHT is biologically 
active, and that recombinant soluble LIGHT can be used as an alternative to native LIGHT in in
vitro experiments. In paper II we show that recombinant soluble LIGHT at 1-100 ng/mL is a potent 
inducer of the adhesion molecules E-selectin and VCAM-1 as well as the chemokines MCP-1 and 
IL-8 in endothelial cells. Importantly, these effects were not only seen in our experiments using 
recombinant LIGHT, but also with platelet-derived LIGHT. Thus, although the amount of platelet-
derived LIGHT is relatively small as compared to, for example sCD40L (i.e., pg versus ng levels), 
neutralizing antibody against LIGHT significantly reduced the platelet-mediated enhancing effect 
on MCP-1 and IL-8 release in HUVEC, suggesting that platelet-derived soluble LIGHT is 
biologically active and possesses inflammatory properties. Heo et al. recently reported that LIGHT 
also had the ability to enhance monocytes activation188, and our findings in paper II suggest that 
recombinant as well as platelet-derived LIGHT enhance the release of MCP-1 and IL-8 from 
monocytes, however, in a modest way as compared to HUVEC. While we previously have shown 
enhancing effects of recombinant CD40L on the release of IL-8 and MCP-1 only at concentrations 
above 1 Pg/mL 189, similar effects of recombinant LIGHT was seen at a concentration of 1 ng/mL 
further underscoring that soluble LIGHT is a potent inducer of platelet-mediated inflammation.
Up-regulation of adhesion molecules and chemokines in endothelial cells is an important 
step in the recruitment and activation of leukocytes into inflamed tissue such as an atherosclerotic 
plaque. The LIGHT-mediated effects on endothelial cells as shown in paper II could therefore 
clearly be relevant to its potential role in atherogenesis. Moreover, Wei et al. demonstrated 
enhancing effects of LIGHT on macrophage migration as well as on SMC proliferation190, and 
LIGHT has also been shown to increase the expression of TF and PAI-1 as well as to enhance 
thrombin formation and MMP activity in macrophages, transforming these cells into a pro-
thrombotic and matrix degrading phenotype.184, 185 Moreover, Scholz et al. have recently showed 
that LIGHT enhances lipid accumulation in oxLDL stimulated THP-1 macrophages possibly 
involving up-regulation of SR-A. The ability of LIGHT to modulate lipid metabolism was further 
supported in a recent study by Lo et al showing that dysregulation of LIGHT expression in T cells 
in mice resulted in hyperlipidemi at least partly by modulating the hepatic lipoprotein lipase 
activity.191 Taken together, these observations indicate that LIGHT could serve as a molecular link 
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between lipid metabolism, inflammation, thrombus formation, and matrix degrading, features that 
all are present in atherosclerotic plaques. These findings also suggest that the raised LIGHT levels 
in CAD patients, seen both in plasma and within the atherosclerotic lesions, may represent 
important pathogenic processes in patients. Future studies should investigate if all these effects of 
LIGHT could be induced by relevant concentrations of platelet-derived LIGHT.
7.4 Activin A: a potential anti-imflammatory actor in CAD and plaque 
destabilization 
As previously described, inflammation is a multifaceted process occurring at cellular, tissue, and 
systemic levels, mediated by the release of a range of cytokines. The balance between 
inflammatory (e.g., TNFĮ, IL-6,) and anti-inflammatory cytokines (e.g., IL-10) seems be of critical 
importance in the pathogenesis of plaque formation and destabilization, and we and others have 
suggested an inflammatory imbalance in unstable disease with “inadequately” raised IL-10 
levels.97 Our findings in paper I suggest that activin A could represent an additional anti-
inflammatory actor in CAD.  
Activin A is a member of the TGF-ȕ superfamily and like TGF-ȕ isoforms primarily 
signals via Smad2 and Smad3. Follistatin regulates activin A bioactivity by preventing activin from 
interacting with its signaling receptors, and this activin-binding protein is also a target of Smad2/3 
signaling, representing a short-loop feedback system. We have recently shown that activin A may 
play a role in the development of heart failure.192 Activin A has also been shown to be involved in 
inflammatory bowel disease114, pulmonary fibrosis193, asthma194, inflammatory arthropathies195,
and has also reported to be rapidly released into circulation following endotoxin administration.196
A potential role for activin A in atherosclerosis was first supported by its demonstration within 
atherosclerotic lesions.197, 198 Later studies have emphasized a link between activin A and 
atherogenesis by showing that activin A could inhibit foam cell formation, induce a non-contractile 
SMC phenotype as well as prevent intimal vascular hyperplasia.115, 199, 200 Based on these 
properties, it was conceivable to hypothesize a role for activin A in the pathogenesis of CAD and 
ACS. In paper I, we show that patients with CAD have elevated levels of activin A, but unlike the 
pattern for several inflammatory cytokines81, 201, 202, only those with stable angina displayed 
enhanced gene expression of this cytokine in PBMC. Furthermore, in contrast to the enhanced 
expression of downstream activin A mediators (i.e., Smad3) in PBMC from stable angina patients 
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as compared with healthy controls, no changes (i.e., Smad3) or even a down-regulation (Smad2) 
was seen in unstable disease. Likewise, the activin type II receptors, representing the primary 
ligand-binding protein, were down-regulated in unstable as compared to stable disease. Thus, 
although activin A and related parameters seem to be up-regulated in CAD, they show a different 
pattern than several inflammatory cytokines, with no changes or even down-regulated levels in 
unstable disease. Our findings in paper I showing that a decrease in serum levels of activin A after 
a mechanically induced plaque rupture (i.e., PCI) was accompanied by increased levels of its 
natural inhibitor (i.e., follistatin), further support decreased activin A activity during plaque 
destabilization.
Activin A has previously been implicated as a stimulator in the production of inflammatory 
cytokines in macrophages203 as well as an inducer of monocyte chemotaxis204 and vascular SMC 
differentiation.115, 199, 200 Activin A has also been reported to increase IL-6 and IL-8 expression 
during pregnancy.205 However, activin A seems to have complex immunomodulatory properties 
and the dichotomy between pro-and anti-inflammatory actions appears to be a central aspect of 
activin A biology. Thus, although the inflammatory effects are well documented, anti-
inflammatory actions have also been reported such as antagonizing effects of IL-6 in different cell 
types.206 Activin A has also been shown to inhibit the IL-6-mediated secretion of acute phase 
proteins.207 A major finding in paper I was that while activin A dose-dependently suppressed the 
release of inflammatory cytokines (i.e., IL-6, IL-8 and MIP-1Į) from PBMC in stable and unstable 
angina, an opposite effect was found in healthy controls. The reason for these different responses 
in PBMC from angina patients and healthy controls is unclear at present, but may involve several 
factors such as different expression pattern of the activin A receptors and Smads. Feinberg et al. 
demonstrated that TGF-ȕ inhibited chemokine expression through Smad-related pathways208, and 
it is possible that the activin A-mediated inhibition of inflammatory cytokines may involve similar 
mechanisms. Moreover, it is well known the effect of various cytokines may largely depend on a 
different degree of cell pre-activation and the presence of co-activators and co-repressors, and such 
factors could clearly be involved in the apparently conflicting reports of immunomodulatory 
effects of activin A. Thus, while activin A could induce inflammatory responses PBMC from 
healthy controls, the stimulation of PBMC from angina, being pre-activated in vivo during their 
interactions with several inflammatory mediators, could result in down-regulation of inflammatory 
responses. We have recently shown that activin A induces anti-inflammatory and anti-oxidative 
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responses in endothelial cells that are pre-activated with IL-1E, but not in unstimulated cells 
(Smith C, Aukrust P, unpublished data), further supporting such a notion.
Activin A has been suggested to promote plaque stabilization by inhibiting foam cell formation 
through regulating scavenger receptor mRNA expression and by inducing a contractile, non-
proliferative phenotype in cultured SMC.115, 199, 200 In paper I we show potent anti-inflammatory 
effects of activin A in PBMC form angina patients, suggesting that an "inadequate rise" in activin 
A could contribute to an inappropriate inflammatory response in these patients. These findings 
may suggest an anti-inflammatory potential for this cytokine in CAD, and down-regulation of the 
activin system may be of importance in the progression from stable to unstable disease. 
Interestingly, the TGF-E type II receptor has been reported to be profoundly decreased in advanced 
atherosclerotic lesions, and disruption TGF-E signaling in T cells has been found to accelerate 
atherosclerosis. It is tempting to hypothesize that also dysregulated expression of activin A and its 
receptors, being a related member of the TGF-E superfamily, could contribute to atherogenesis and 
plaque destabilization. 
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8. Concluding remarks 
x Stable angina patients were characterized by increased plasma levels and increased gene 
expression in PBMC of activin A. In contrast, the gene expression of activin A as well as the 
activin type II receptor was decreased in PBMC from unstable angina patients. A decreased 
ratio between activin A and its natural inhibitor follistatin was seen in patients undergoing PCI, 
further suggesting decreased activin A activity during plaque rupture. Activin A suppressed the 
release of inflammatory cytokines in PBMC from CAD patients, with an opposite response in 
cells from healthy controls. These findings suggest a potential anti-inflammatory and 
beneficial effect of activin A in atherogenesis and plaque destabilization. 
x Upon activation, platelets release soluble LIGHT, a member of the TNF superfamily, in a 
gradual manner, different from the rapid release from D-granules. The release involves GP 
IIb/IIIa dependent mechanisms and action of metal-dependent proteases as well as intracellular 
processes such as actin polymerization. Platelet-derived LIGHT is biologically active and 
induces inflammatory responses in monocytes and in particular in endothelial cells. Thrombus 
materials, obtained at the site of plaque rupture in STEMI patients, contains platelet-associated 
LIGHT suggesting that LIGHT-mediated inflammation also is operating in vivo. Our findings 
suggest that LIGHT should be added to the list of mediators that are involved in platelet-
mediated inflammation, potentially contributing to vascular inflammation in atherosclerotic 
disorders.
x CAD patients had raised plasma levels of NAP-2 with particularly high concentrations in those 
with unstable disease, accompanied by increased expression of its receptor CXCR2 in 
monocytes. Even though NAP-2 is considered to be a predominantly platelet-derived 
chemokine, PBMC were found to release large amounts of NAP-2 upon stimulation, in 
particular in CAD patients. NAP-2 protein was localized to macrophages and vascular SMC of 
atherosclerotic carotid plaques and in monocytes and platelets of coronary thrombi of STEMI 
patients. In vitro, recombinant and platelet-derived NAP-2 increased the expression of 
adhesion molecules and chemokines in endothelial cells. While there are several reports on 
IL-8 in human CAD, our data suggest that another CCR2 ligand (i.e., NAP-2) has the 
potential to induce inflammatory responses within the atherosclerotic plaque, and such a 
NAP-2-driven inflammation could ultimately lead to plaque rupture and ACS.
x CAD patients had increased plasma levels of CCL19 and CCL21, accompanied by decreased 
expression of their common receptor CCR7 in PBMC, with the most marked changes in those 
with unstable disease. In contrast to the decreased CCR7 expression in circulating T cells from 
CAD patients, strong CCR7 immunostaining was seen in T cells within the atherosclerotic 
54
lesions of both murine and human atherosclerosis, accompanied by strong immunoreactivity of 
CCL19 and CCL21 in macrophages and vascular SMC within the atherosclerotic plaques. In
vitro, CCL19 and CCL21 were shown to induce an inflammatory, matrix degrading, and pro-
thrombotic phenotype in macrophages. The abnormal regulation of CCL19 and CCL21 and 
their common receptor CCR7 in atherosclerosis could contribute to disease progression by 
recruiting T cells to the atherosclerotic lesions and by promoting inflammatory responses in 
T cells and macrophages within the plaque. 
x CAD patients had raised plasma concentrations of the transmembrane chemokine CXCL16, 
and these levels were down-regulated by statins both in vivo and in vitro, at least partly 
involving inhibition of the protease ADAM10. CXCL16 induced the production of 
inflammatory chemokines in PBMC, most prominently in CAD patients, and enhanced the 
secretory potential of inflammatory mediators in vascular SMC. Our findings suggest that 
CXCL16 could be linked to atherogenesis not only as a marker of inflammation, but also as 
a potential inflammatory mediator.
Our findings further underscore the role of inflammation in the pathogenesis of 
atherosclerosis and plaque destabilization, involving interactions between platelets, endothelial 
cells, macrophages, T cells, and vascular SMC. Our findings also suggest that while NAP-2, 
CXCL16, CCL19, CCL21, and LIGHT could enhance these inflammatory interactions, activin 
A could attenuate these processes. Future studies should further characterize the pathogenic 
role and the relative importance of these mediators, with the ambitions to delineate novel 
therapeutic targets possibly leading to new treatment modalities in atherosclerotic disorders.   
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